Positive ER/PR and negative HER2 status is used in the COMET trial as inclusion criteria for the active surveillance regimen [7] in keeping with the data presented here; when DCIS shows ER negativity and/or HER2 positivity, classification as high‐grade DCIS should be considered. Here, ERBB2 is linked to ductal breast carcinoma in situ.